Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling.

Article Details

Citation

Copy to clipboard

Deng G, Liu Z, Ye F, Luo X, Zhu W, Shen X, Liu H, Jiang H

Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling.

Eur J Med Chem. 2008 Dec;43(12):2699-716. doi: 10.1016/j.ejmech.2008.01.032. Epub 2008 Feb 3.

PubMed ID

18329752 [ View in PubMed

]

Abstract

The discovery of peroxisome proliferator-activated receptor gamma (PPARgamma) antagonists (also termed "selective PPARgamma modulators, SPPARgammaM") is now of a great interest in the treatment of diabetes and obesity. The structure of compound 1a (G3335, Fig. 1), a novel class of PPARgamma antagonist, is entirely different from that of other reported PPARgamma antagonists. A series of 35 novel analogues (1b-l, 9a-d, 13a-t) were designed, synthesized and evaluated against the agonistic effects exerted by rosiglitazone. These results indicated that most functional groups of 1a were conserved, and six new compounds (1b, 1c, and 9a-d) exhibited strong PPARgamma antagonistic activities (IC(50) values of 5.2-25.8 microM) against 10 microM rosiglitazone in the promotion of the PPARgamma-LBD-CBP (ligand-binding domain and cAMP-response-element binding protein) interaction as investigated by yeast two-hybrid technology based assay. Molecular modeling studies for compounds 1a-d, 1h, 9c-d, and 13a were also presented.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
2-chloro-5-nitro-N-phenylbenzamide	Peroxisome proliferator-activated receptor gamma	IC 50 (nM)	3300	N/A	N/A	Details